SAN FRANCISCO - Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in targeted protein modulation drugs, announced today the appointment of John Northcott as its new ...

Try Now>> See the top stocks recommended by analysts >> Read More on NRIX: Nurix Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in ...

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) have been assigned a consensus recommendation of “Moderate ...

8 analysts have expressed a variety of opinions on Nurix Therapeutics NRIX over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you'll find a ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $16.00 ...